The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation
- PMID:9210483
- DOI: 10.1111/j.1432-1033.1997.t01-1-00193.x
The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation
Abstract
The lantibiotic mersacidin has been previously reported to interfere with bacterial peptidoglycan biosynthesis, [Brötz, H., Bierbaum, G., Markus, A., Molitor, E. & Sahl, H.-G. (1995) Antimicrob. Agents Chemother. 39, 714-719]. Here, we focus on the target reaction and describe a mersacidin-induced accumulation of UDP-N-acetylmuramoyl-pentapeptide, indicating that inhibition of peptidoglycan synthesis occurs after the formation of cytoplasmic precursors. In vitro studies involving a wall-membrane particulate fraction of Bacillus megaterium KM demonstrated that mersacidin did not prevent the synthesis of lipid II [undecaprenyl-diphosphoryl-N-acetylmuramoyl-(pentapeptide)-N-ac ety lglucosamine] but specifically the subsequent conversion of this intermediate into polymeric nascent glycan strands by transglycosylation. Comparison with other inhibitors of transglycosylation shows that the effective concentration of mersacidin in vitro is in the range of that of the glycopeptide antibiotic vancomycin but 2-3 orders of magnitude higher than that of the competitive enzyme inhibitor moenomycin. The analogy to the glycopeptides may hint at an interaction of mersacidin with the peptidoglycan precursor rather than with the enzyme. Unlike vancomycin however, mersacidin inhibits peptidoglycan formation from UDP-N-acetylmuramoyl-tripeptide and is active against Enterococcus faecium expressing the vanA resistance gene cluster. This indicates that the molecular target site of mersacidin differs from that of vancomycin and that no cross-resistance exists between the two antibiotics.
Similar articles
- Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism?Brötz H, Bierbaum G, Markus A, Molitor E, Sahl HG.Brötz H, et al.Antimicrob Agents Chemother. 1995 Mar;39(3):714-9. doi: 10.1128/AAC.39.3.714.Antimicrob Agents Chemother. 1995.PMID:7793878Free PMC article.
- The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II.Brötz H, Bierbaum G, Leopold K, Reynolds PE, Sahl HG.Brötz H, et al.Antimicrob Agents Chemother. 1998 Jan;42(1):154-60. doi: 10.1128/AAC.42.1.154.Antimicrob Agents Chemother. 1998.PMID:9449277Free PMC article.
- Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic.Allen NE, Hobbs JN Jr, Nicas TI.Allen NE, et al.Antimicrob Agents Chemother. 1996 Oct;40(10):2356-62. doi: 10.1128/AAC.40.10.2356.Antimicrob Agents Chemother. 1996.PMID:8891144Free PMC article.
- Antimicrobial mechanism of lantibiotics.Islam MR, Nagao J, Zendo T, Sonomoto K.Islam MR, et al.Biochem Soc Trans. 2012 Dec 1;40(6):1528-33. doi: 10.1042/BST20120190.Biochem Soc Trans. 2012.PMID:23176511Review.
- Docking on Lipid II-A Widespread Mechanism for Potent Bactericidal Activities of Antibiotic Peptides.Grein F, Schneider T, Sahl HG.Grein F, et al.J Mol Biol. 2019 Aug 23;431(18):3520-3530. doi: 10.1016/j.jmb.2019.05.014. Epub 2019 May 14.J Mol Biol. 2019.PMID:31100388Review.
Cited by
- Investigation into the mechanism of action of the antimicrobial peptide epilancin 15X.Wu C, Lower BA, Moreira R, Dorantes D, Le T, Giurgiu C, Shi Y, van der Donk WA.Wu C, et al.Front Microbiol. 2023 Nov 2;14:1247222. doi: 10.3389/fmicb.2023.1247222. eCollection 2023.Front Microbiol. 2023.PMID:38029153Free PMC article.
- New insights into the mode of action of the lantibiotic salivaricin B.Barbour A, Tagg J, Abou-Zied OK, Philip K.Barbour A, et al.Sci Rep. 2016 Aug 16;6:31749. doi: 10.1038/srep31749.Sci Rep. 2016.PMID:27526944Free PMC article.
- Specific Binding of the α-Component of the Lantibiotic Lichenicidin to the Peptidoglycan Precursor Lipid II Predetermines Its Antimicrobial Activity.Panina IS, Balandin SV, Tsarev AV, Chugunov AO, Tagaev AA, Finkina EI, Antoshina DV, Sheremeteva EV, Paramonov AS, Rickmeyer J, Bierbaum G, Efremov RG, Shenkarev ZO, Ovchinnikova TV.Panina IS, et al.Int J Mol Sci. 2023 Jan 10;24(2):1332. doi: 10.3390/ijms24021332.Int J Mol Sci. 2023.PMID:36674846Free PMC article.
- Molecular mechanism of target recognition by subtilin, a class I lanthionine antibiotic.Parisot J, Carey S, Breukink E, Chan WC, Narbad A, Bonev B.Parisot J, et al.Antimicrob Agents Chemother. 2008 Feb;52(2):612-8. doi: 10.1128/AAC.00836-07. Epub 2007 Nov 12.Antimicrob Agents Chemother. 2008.PMID:17999970Free PMC article.
- Antimicrobial Peptides as Anti-Infective Agents in Pre-Post-Antibiotic Era?Rončević T, Puizina J, Tossi A.Rončević T, et al.Int J Mol Sci. 2019 Nov 14;20(22):5713. doi: 10.3390/ijms20225713.Int J Mol Sci. 2019.PMID:31739573Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical